X0206 3 2015-10-26 0 0001069308 Opexa Therapeutics, Inc. OPXA 0001643067 Healey Don C/O OPEXA THERAPEUTICS, INC. 2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS TX 77381 0 1 0 0 Chief Scientific Officer Common Stock 4045 D Employee Stock Option (right to buy) 72.04 2020-04-30 Common Stock 937 D Employee Stock Option (right to buy) 49.95 2021-01-04 Common Stock 937 D Employee Stock Option (right to buy) 30.4 2022-01-06 Common Stock 1308 D Employee Stock Option (right to buy) 30.4 2022-01-06 Common Stock 2617 D Employee Stock Option (right to buy) 30.4 2022-01-06 Common Stock 1199 D Employee Stock Option (right to buy) 14 2023-04-29 Common Stock 2500 D Employee Stock Option (right to buy) 14.56 2024-02-28 Common Stock 8078 D Employee Stock Option (right to buy) 6.56 2025-03-02 Common Stock 7500 D The option vests quarterly on the anniversary of the date of grant over a period of three years. The performance-based options began vesting quarterly over a three year-period upon achievement of certain key milestone events. On September 12, 2012, the first tranche of one-third of the performance option shares commenced three-year quarterly vesting upon achievement of the first key milestone, which was Opexa Therapeutics, Inc. (the "Company") initiating a clinical trial for its product candidate Tcelna in Secondary Progressive Multiple Sclerosis. On February 5, 2013, the second tranche of two-thirds of the performance option shares commenced three-year quarterly vesting upon achievement of the second key milestone, which was the Company entering into a collaboration, partnership or other strategic arrangement involving rights in the United States for Tcelna. 25% of the shares vest on the one-year anniversary of the grant date, and the remaining 75% vest quarterly over the remaining three years. Exhibit List: Exhibit 24 - Power of Attorney /s/ Don Healey 2015-11-03